PENTHROX METHOXYFLURANE
Low-dose inhaled analgesia in prehospital emergencies, remote medicine, offshore care, rescue operations, emergency departments, TACMED, and austere environments
Scientific, pharmacological, regulatory, tactical, and medico-operational review updated to 2026
DrRamonReyesMD
EMS Solutions International
INTRODUCTION
Acute pain control is not a healthcare luxury. It is a clinical, humanitarian, physiological, operational, and tactical intervention. A patient in severe pain ventilates worse, cooperates less, mobilizes poorly, consumes more catecholamines, increases myocardial oxygen demand, develops a greater neuroendocrine stress response, and may complicate evacuation, physical examination, immobilization, and decision-making.
In prehospital medicine, remote medicine, rescue, offshore environments, mountain medicine, ambulance care, rural emergency care, mass-casualty incidents, and tactical settings, pain also has an operational dimension: the patient who cannot cooperate becomes a greater logistical burden; the wounded casualty who screams may compromise security in tactical scenarios; and the polytrauma patient with extreme pain may be undertreated or overtreated if a proportional, safe, and tiered analgesic strategy is not available.
Within this context appears Penthrox, the commercial name for low-dose inhaled methoxyflurane, popularly known in Australia and New Zealand as the “green whistle”. Its appeal is obvious: it is small, portable, non-intravenous, rapid-onset, self-administered under healthcare supervision, useful for moderate to severe traumatic pain in conscious adults, and particularly interesting when establishing intravenous access delays analgesia or consumes resources.
But Penthrox is not magic. It is not inhaled morphine. It is not ketamine. It is not general anaesthesia. It is not a drug for chronic pain. It is not for unconscious patients. It is not for every type of pain. It must not be trivialised simply because it is easy to use. It is a very useful tool when its pharmacology, indication, analgesic ceiling, real risks, and operational limits are properly understood.
This article updates and expands the original EMS Solutions International content on Penthrox, incorporating evidence available up to 2026, European and Spanish regulation, the United States context, its role in remote and offshore medicine, its comparison with ketamine, fentanyl, morphine, NSAIDs, and paracetamol/acetaminophen, and its current absence from TCCC protocols as a standard combat analgesic.
WHAT IS METHOXYFLURANE?
Methoxyflurane is a volatile halogenated ether historically used as an inhalational anaesthetic. At high anaesthetic doses and with prolonged exposure, its use was associated with nephrotoxicity and hepatotoxicity, which led to its abandonment as a general anaesthetic in many countries.
The modern key point is that Penthrox does not use methoxyflurane as a general anaesthetic, but as a low-dose inhaled analgesic. The difference is not semantic: it is pharmacological, toxicological, and clinical. The historical renal and hepatic risks came mainly from exposures much higher than those used for emergency analgesia. Even so, that history requires strict respect for maximum dose, contraindications, and patient selection.
Penthrox is administered through a portable inhaler that usually contains 3 ml of methoxyflurane. The conscious patient inhales through the device and can partially modulate analgesic intensity according to breathing pattern. The system includes an activated carbon chamber to reduce occupational exposure of healthcare personnel to exhaled vapour.
INDICATION IN SPAIN AND EUROPE
In Spain, according to the product information available through CIMA-AEMPS, Penthrox 99.9% liquid for inhalation vapour is authorised for the emergency relief of moderate to severe pain associated with trauma in conscious adult patients.
This is important. The indication is not “all pain”. It is not chronic pain. It is not undifferentiated abdominal pain. It is not sedation. The formal indication is moderate to severe traumatic pain in a conscious adult.
Within the European framework, the authorised indication is essentially equivalent: emergency relief of moderate to severe pain in conscious adults with trauma and associated pain. Some countries and local protocols may expand or adapt its use for specific procedures or services, but the core indication remains acute traumatic pain of moderate to severe intensity.
In the United Kingdom, Scotland, Ireland, Canada, Australia, New Zealand, and other countries, Penthrox has been incorporated to varying degrees into emergency departments, ambulance services, rescue systems, rural services, and short painful procedures. Its adoption is not uniform because it depends on regulation, funding, analgesic culture, opioid availability, staff training, and cost-benefit assessment.
SITUATION IN THE UNITED STATES
In the United States, methoxyflurane has a different regulatory history. The old Penthrane formulation, used as an inhalational anaesthetic, was withdrawn from the US market. The FDA determined that it had been withdrawn for reasons of safety or effectiveness, particularly because of concerns regarding nephrotoxicity and hepatotoxicity.
This point has strongly influenced the American perception of the drug. For many North American clinicians, methoxyflurane mentally equals an old anaesthetic with renal toxicity. However, that comparison may be unfair if one does not distinguish between high-dose anaesthetic exposure and low-dose analgesic exposure. The problem is that regulatory memory carries weight, and approval of a product requires trials, investment, pharmacovigilance, and institutional acceptance.
Therefore, the reason why the United States does not use it widely is not that “it does not work”. The real explanation combines safety history, regulation, absence of broad modern approval, availability of alternatives such as ketamine and fentanyl, an EMS culture based on opioids and ketamine, and the need for local evidence to convince highly regulated medical systems.
DOSAGE AND ADMINISTRATION
The usual adult regimen is one 3 ml bottle inhaled through the specific device. A second 3 ml bottle may be used if necessary, while respecting the maximum recommended dose.
In practical terms, the device allows rapid-onset analgesia, usually perceived within a few minutes. The duration of one administration may range from approximately 25 to 60 minutes depending on breathing pattern, intensity of use, and inhalation technique.
It must be used under the supervision of trained healthcare personnel. It must not be handed out as a domestic product. It is not for free self-medication. It does not replace clinical assessment or definitive treatment of the injury.
The patient must be conscious, able to understand instructions, maintain the airway, hold the device, and cooperate. If the patient is unconscious, confused, intoxicated, neurologically impaired, ventilatorily compromised, or unable to cooperate, Penthrox is no longer a good option.
PHARMACOLOGY AND MECHANISM OF ACTION
The exact analgesic mechanism of low-dose methoxyflurane cannot be reduced to a single molecular target. As a volatile halogenated agent, it acts on multiple neuronal systems involved in nociceptive modulation, including ion channels, inhibitory and excitatory synaptic transmission, and central pain processing.
Its clinical usefulness comes from a combination of properties:
rapid onset through inhalation,
absence of intravenous puncture,
partial self-titration,
brief analgesic effect,
portability,
logistical simplicity,
lower monitoring burden than potent opioids or ketamine in many scenarios,
and the possibility of early administration before vascular access is obtained.
It does not provide unlimited analgesia. In extreme severe pain, major trauma, polytrauma, amputation, extensive burns, or injuries with haemodynamic compromise, it may be insufficient as monotherapy. In those cases, it must be integrated into a multimodal and tiered strategy.
REAL CLINICAL ADVANTAGES
The main advantage of Penthrox is that it allows rapid analgesia without intravenous access. In prehospital care, this is huge. Establishing vascular access may be difficult in cold weather, darkness, rain, shock, obesity, paediatric patients, maritime environments, mountain rescue, moving ambulances, or mass-casualty incidents.
The second advantage is portability. The device is small, light, and easy to carry in medical bags, ambulances, rescue units, offshore facilities, mining operations, industry, sports events, ski stations, ships, platforms, helicopters, and rural environments.
The third advantage is supervised self-administration. The conscious patient can modulate inhalation. This reduces the risk of inadvertent overdosing compared with parenteral analgesics administered in repeated boluses without adequate monitoring.
The fourth advantage is that it is not an opioid. This avoids issues of custody, theft, abuse, typical opioid respiratory depression, and regulatory barriers associated with controlled substances in certain countries or companies.
The fifth advantage is that it does not require refrigeration or infusion pumps. In remote and offshore medicine, pharmaceutical logistics are as important as pharmacology.
The sixth advantage is its usefulness as bridge analgesia. It can relieve pain while immobilisation, simple reduction, transfer, venous access, additional analgesia, or advanced medical assessment is being prepared.
REAL LIMITATIONS
Penthrox does not completely eliminate pain in every patient. It reduces pain intensity, but it should not be presented as absolute analgesia.
It is not ideal for very severe pain with VAS/NRS 9–10 if deep or dissociative analgesia is required. In those cases, ketamine, titrated opioids, or regional anaesthesia may be superior.
It is not appropriate for unconscious or non-cooperative patients.
It is not appropriate when significant neurological deterioration, intoxication, relevant respiratory difficulty, or inability to manage the inhaler is suspected.
It is not appropriate for chronic pain, repetitive pain, or frequent use.
It has a strict maximum dose. It cannot be repeated indefinitely.
It may cause dizziness, drowsiness, euphoria, nausea, cough, a feeling of intoxication, or transient impairment of the ability to drive or operate machinery.
It must be avoided in patients with relevant renal, hepatic, cardiovascular, or respiratory contraindications according to the local product information.
RENAL RISK
Renal risk is the great historical ghost of methoxyflurane. At high anaesthetic doses, methoxyflurane metabolism can generate inorganic fluoride and other metabolites implicated in nephrotoxicity. That historical precedent is real and must not be denied.
However, modern analgesic use employs much lower doses, with much lower exposure. Post-authorisation safety studies and international experience have not shown a signal comparable to historical anaesthetic toxicity when dose limits, intervals, and contraindications are respected.
The correct conclusion is not “there is no renal risk”. The correct conclusion is: severe renal risk appears low with authorised analgesic doses and appropriate patient selection, but it increases if doses are exceeded, if the drug is repeated inappropriately, or if there is pre-existing kidney disease, dehydration, shock, sepsis, poorly controlled diabetes, concomitant nephrotoxic drugs, or cumulative exposure.
In operational medicine, this means that Penthrox may be excellent for an isolated fracture in a conscious adult, but it should be reconsidered in a polytrauma patient, a hypotensive patient, a dehydrated patient, a patient with probable rhabdomyolysis, previous renal injury, or exposure to nephrotoxic drugs.
HEPATIC RISK
Hepatic risk also comes from the history of halogenated anaesthetics. Methoxyflurane may rarely be associated with liver injury, especially in patients with a history of liver damage after methoxyflurane or halogenated anaesthetics.
It must be avoided in patients with previous hepatic injury after methoxyflurane or halogenated hydrocarbons. It must be used cautiously in liver disease, exposure to enzyme-inducing drugs, or situations that may increase hepatic susceptibility.
In remote settings, where immediate laboratory testing may not be available, clinical selection should be conservative. If the patient reports significant liver disease, previous jaundice after anaesthesia, active hepatopathy, or recent repeated exposure to methoxyflurane, it is not the ideal drug.
MALIGNANT HYPERTHERMIA
As a halogenated agent, Penthrox is contraindicated in patients with known or suspected susceptibility to malignant hyperthermia. This includes compatible personal or family history.
Although the analgesic dose is low, the contraindication must be respected. Malignant hyperthermia is a potentially fatal pharmacogenetic emergency associated with volatile anaesthetics and succinylcholine, characterised by hypercapnia, rigidity, hyperthermia, acidosis, rhabdomyolysis, hyperkalaemia, and cardiovascular collapse.
USE IN SPAIN
In Spain, Penthrox is authorised and available according to the AEMPS-CIMA product information for conscious adults with moderate to severe pain associated with trauma. Its real-world implementation depends on the service, autonomous community, hospital, emergency department, ambulance provider, or local protocol.
Its potential value in Spain is high in:
hospital emergency departments,
primary care emergency settings,
urgent care centres,
advanced life support ambulances,
mountain rescue,
beach rescue,
sports events,
rural areas,
painful transfers,
patients with fractures, dislocations, contusions, limited burns, or acute musculoskeletal injuries.
Its main barrier is not scientific but organisational: cost, training, centralised purchasing, protocol inclusion, staff familiarity, historical fear of toxicity, availability of cheaper alternatives, and regional variability.
USE IN EUROPE
In Europe, Penthrox has gradually occupied a role as a rapid analgesic for moderate to severe trauma pain in conscious adults. Penetration is uneven. The United Kingdom, Ireland, and some European services use it in emergency departments and prehospital care. France evaluated its usefulness, recognising superiority over placebo, but also noted limitations in high-quality comparative evidence against other analgesics and less clarity in very severe pain.
This is important: the fact that a drug is useful does not mean it is superior in every context. The strongest evidence supports it as rapid analgesia versus placebo or standard treatment in selected scenarios, but direct comparison against ketamine, intranasal fentanyl, intravenous morphine, or regional anaesthesia still depends on heterogeneous studies.
AUSTRALIA AND NEW ZEALAND
Australia and New Zealand are the emblematic countries for inhaled methoxyflurane use. There it has been part of prehospital culture for decades. The “green whistle” is familiar to ambulance services, rescue teams, sports medicine, rural settings, and armed forces.
Why do they use it with less fear? Because their historical experience clearly distinguishes old anaesthetic use from low-dose analgesic use; because the system has incorporated it with training and protocols; because it has demonstrated practical utility over long distances; and because Australian and New Zealand prehospital medicine has highly valued portable, non-intravenous solutions.
This does not mean they use it without rules. They use it with maximum dose limits, contraindications, monitoring, and protocols.
REMOTE AND OFFSHORE MEDICINE
In offshore medicine, oil and gas platforms, ships, mining, jungle, desert, islands, remote bases, and industrial camps, Penthrox has a very attractive profile.
Its advantages in these environments are:
low volume,
easy storage,
rapid onset,
no need for intravenous access,
usefulness during prolonged evacuation,
lower complexity than parenteral opioids,
fewer custody problems than fentanyl or morphine,
possibility of supervised administration by trained personnel under telemedicine support.
In offshore settings, where the physician may be remote or where the paramedic needs to stabilise the patient for hours before evacuation, Penthrox can be an excellent first step for moderate to severe traumatic pain if the patient is conscious and has no contraindications.
But it does not replace morphine, fentanyl, ketamine, regional blocks, or evacuation. It is a bridge tool, not a complete solution.
TACTICAL, MILITARY, AND NATO MEDICINE
The tactical question is inevitable: if Penthrox is so good, why is it not universally adopted by TCCC, NATO, or top-tier military forces?
The answer is multifactorial.
First, TCCC prioritises drugs with robust efficacy in severe combat pain, shock, amputations, penetrating injuries, burns, open fractures, and tactical evacuation. In that environment, ketamine has very strong advantages: potent analgesia, relative preservation of respiratory drive, usefulness in shock, multiple administration routes, and accumulated military experience.
Second, combat produces patients who cannot always cooperate. Penthrox requires a conscious patient able to inhale and follow instructions. A casualty under fire, agitated, hypoxic, with traumatic brain injury, massive haemorrhage, shock, or altered mental status is not the ideal candidate.
Third, the smell/vapour and inhaled administration may not be ideal in closed tactical spaces, vehicles, aircraft, or scenarios requiring concealment, although this depends on context.
Fourth, duration is limited and repetition is restricted by maximum dose. In prolonged military evacuations, this may be a disadvantage compared with titratable strategies.
Fifth, United States and NATO military logistics already have established chains for ketamine, opioids, paracetamol/acetaminophen, antibiotics, and blood products. Introducing a volatile agent with a complex regulatory history requires strong doctrinal justification.
Sixth, historical toxicology carries weight. Even though low-dose use is different, military committees are conservative with drugs that have prior nephrotoxicity and hepatotoxicity concerns.
Therefore, the absence of Penthrox from TCCC does not mean it is a bad drug. It means it does not fit the current combat algorithm as well as ketamine, esketamine, and oral analgesic strategies.
TCCC 2026 AND ANALGESIA
The 2026 TCCC guidelines maintain ketamine and esketamine as central options for analgesia administered by medical personnel. Ketamine may be administered intramuscularly, intranasally, intravenously, or intraosseously, with repeated dosing according to response. The guidelines also maintain the need to disarm or consider disconnecting communications in patients receiving ketamine because of the risk of perceptual disturbance or unsafe behaviour.
This illustrates the TCCC philosophy: a potent drug with psychoperceptual effects is accepted because combat pain can be extreme and because ketamine works in settings where opioids may compromise respiration or blood pressure.
Penthrox could have a role as tactical analgesia in selected missions, patrols, rescue operations, training, law enforcement tactical medicine, protective medicine, search and rescue, or peacekeeping environments, but it does not displace ketamine in major combat trauma.
ISRAEL AND THE IDF
Israel has an extraordinarily pragmatic military medical culture, oriented toward haemorrhage control, rapid evacuation, damage control, and highly efficient prehospital treatment. If a drug is not widely protocolised in a system such as Israel’s, the reason is usually operational, not ideological.
In IDF-type scenarios, Magen David Adom, tactical units, terrorist attacks, penetrating trauma, explosions, mass casualties, and rapid evacuation, analgesia must be potent, reliable, scalable, and compatible with shock, haemorrhage, and altered mental status. Ketamine and titrated opioids have historically been more adaptable to that spectrum.
Penthrox may be useful in isolated injuries, fractures, civilian evacuation, rescue, or moderate to severe pain in a stable patient, but it is not the natural centre of Israeli military analgesia for high-intensity combat.
COMPARISON WITH KETAMINE
Ketamine is superior when pain is severe, the patient is in shock, or there is risk of haemodynamic instability. It has greater analgesic potency, can be administered IM, IN, IV, or IO, allows sub-dissociative or dissociative dosing, and is useful in major trauma.
Its disadvantages are:
emergence reactions,
nystagmus,
hypersalivation,
nausea,
perceptual disturbance,
possible agitation,
need for greater monitoring,
operational risk in an armed patient,
and need for more robust training.
Penthrox wins in simplicity, portability, speed without IV access, self-administration, and lower complexity. It loses in potency, duration, usefulness in non-cooperative patients, and major trauma.
Conclusion: Penthrox is excellent for moderate to severe traumatic pain in a conscious and stable patient; ketamine is more robust for severe pain, major trauma, combat, shock, and complicated evacuation.
COMPARISON WITH FENTANYL
Fentanyl is a potent, rapid, and effective opioid. It may be administered IV, IN, transmucosally, or IM depending on formulation. It is very useful in severe pain and allows titration.
Its problems are:
respiratory depression,
nausea,
vomiting,
sedation,
hypotension in some contexts,
abuse risk,
legal custody,
interactions,
regulatory difficulty,
and the sociopolitical fentanyl crisis in the United States.
Penthrox avoids many opioid-related problems and may be easier to deploy in services where opioid custody is complex. However, fentanyl may be more potent and more appropriate for severe pain if monitoring and trained personnel are available.
Conclusion: Penthrox does not replace fentanyl in extreme pain, but it may reduce opioid requirements in moderate to severe traumatic pain and improve time to analgesia when no IV access is available.
COMPARISON WITH MORPHINE
Morphine is classic, cheap, familiar, and effective. Its disadvantage is that it requires IV/SC/IM access depending on context, and may cause hypotension, nausea, vomiting, respiratory depression, pruritus, urinary retention, and delayed administration if vascular access is not available.
Penthrox acts faster in scenarios where IV access delays treatment. Morphine may be better for prolonged pain and hospital titration.
Conclusion: Penthrox is better as early non-invasive analgesia; morphine remains useful as titratable systemic analgesia when monitoring and access are available.
COMPARISON WITH NSAIDs
NSAIDs such as ibuprofen, dexketoprofen, ketorolac, or diclofenac are effective in inflammatory pain, musculoskeletal pain, renal colic, and minor to moderate trauma. They are cheap and non-sedating.
Their risks include:
gastrointestinal bleeding,
renal failure,
bronchospasm in susceptible patients,
worsening hypertension,
cardiovascular risk,
interaction with anticoagulants,
risk in elderly patients,
and relative contraindication in trauma with bleeding, hypovolaemia, or renal insufficiency.
In tactical or remote trauma, NSAIDs must be used prudently. In a bleeding, dehydrated, shocked, or potentially surgical patient, they may not be ideal.
Penthrox does not have the same gastrointestinal bleeding or antiplatelet profile. However, it has its own renal and hepatic limits and is not useful for prolonged treatment.
Conclusion: NSAIDs are good for inflammatory pain and selected mild-to-moderate injuries; Penthrox is better for rapid rescue analgesia in moderate to severe traumatic pain when IV access and opioids are undesirable.
COMPARISON WITH PARACETAMOL / ACETAMINOPHEN
Paracetamol/acetaminophen is safe, cheap, useful, non-sedating, and highly valuable as a multimodal baseline drug. But in many cases it is insufficient for isolated moderate to severe traumatic pain.
Penthrox is much faster and more potent as rescue analgesia, but it does not replace paracetamol/acetaminophen as baseline analgesia. They complement each other well.
Conclusion: paracetamol/acetaminophen is the base; Penthrox is an early rescue tool.
COMPARISON WITH REGIONAL ANAESTHESIA
Ultrasound-guided nerve blocks, femoral nerve block, fascia iliaca block, serratus anterior plane block, erector spinae plane block, intercostal blocks, or digital blocks may be superior in localised pain. They reduce opioid use and provide prolonged analgesia.
But they require:
training,
time,
equipment,
ultrasound,
asepsis,
anatomical knowledge,
anticoagulation assessment,
and a relatively stable environment.
Penthrox wins in speed, simplicity, and mass deployment. Regional analgesia wins in quality and duration when technical capacity exists.
Conclusion: in expert hands, regional blocks may be superior; in rapid prehospital care, Penthrox is more accessible.
COST AND COST-BENEFIT
Penthrox is not cheap compared with paracetamol/acetaminophen, ibuprofen, metamizole/dipyrone, or generic morphine. Its per-dose cost may appear high if only the device price is considered.
But the real cost-benefit assessment must include:
time to analgesia,
avoidance of intravenous access,
lower opioid use,
less need for complex monitoring,
greater patient satisfaction,
faster immobilisation,
less operational delay,
lower narcotic custody burden,
utility in remote locations,
and value in mass-casualty incidents.
In an urban hospital with staff, rapid IV access, and opioids available, it may appear expensive. In a rural ambulance, offshore platform, ski station, mountain environment, island, ship, rescue operation, or police tactical unit, it can be extraordinarily cost-effective.
The correct question is not how much the inhaler costs. The correct question is how much it costs not to control pain for 30 minutes in a patient with a fracture in a remote area.
SCENARIOS WHERE PENTHROX SHINES
Isolated extremity fracture in a conscious adult.
Painful dislocation before reduction or transfer.
Severe contusion.
Limited burn.
Sports trauma.
Mountain rescue.
Maritime evacuation.
Offshore care.
Rural ambulance.
Primary care emergency setting.
Painful transfer.
Patient without IV access.
Mass-casualty incident where rapid analgesia is needed for stable patients.
Moderate to severe pain where opioids are undesirable.
SCENARIOS WHERE IT IS NOT IDEAL
Unstable major trauma.
Haemorrhagic shock.
Altered level of consciousness.
Significant traumatic brain injury.
Respiratory failure.
Non-cooperative patient.
Chronic pain.
Non-traumatic pain not indicated by local product information.
Significant renal insufficiency.
Significant liver disease or previous hepatic injury from halogenated agents.
Suspected malignant hyperthermia susceptibility.
Need for prolonged analgesia.
Pain 10/10 where ketamine, titrated opioid, or regional block is required.
COMMON ADVERSE EFFECTS
The most common adverse effects are dizziness, drowsiness, headache, nausea, feeling intoxicated, euphoria, cough, dry mouth, or transient attention impairment.
Most are mild and transient. However, in operational medicine they matter: a dizzy patient must not walk alone, drive, sign complex decisions, or operate machinery. In vertical rescue, maritime rescue, or industrial rescue, the patient must be physically secured after administration.
HEALTHCARE PERSONNEL SAFETY
Methoxyflurane is volatile. The activated carbon chamber reduces environmental exposure, but staff must use the device correctly, avoid enclosed poorly ventilated spaces, and respect occupational recommendations.
In ambulances, helicopters, enclosed compartments, or ships, ventilation should be considered. Repeated use in confined spaces may have occupational exposure implications.
EMS SOLUTIONS INTERNATIONAL PROPOSED ALGORITHM
Mild pain: paracetamol/acetaminophen, physical measures, immobilisation, local cold if appropriate.
Moderate traumatic pain in a conscious, stable adult: paracetamol/acetaminophen plus Penthrox if available, or NSAID if no contraindications exist.
Moderate to severe traumatic pain without IV access, conscious, stable, cooperative patient: Penthrox as rapid initial analgesia.
Severe pain, major trauma, amputation, shock, or complex evacuation: ketamine/esketamine according to protocol, titrated opioid if indicated, regional analgesia if available, haemostasis and damage control.
Pain with suspected surgical pathology, bleeding, or hypovolaemia: avoid NSAIDs unless the indication is very clear.
Pain in an armed or tactical patient: extreme caution with ketamine; disarm if administered; Penthrox only if the patient is cooperative and the situation allows it.
WHY SOME COUNTRIES USE IT WITHOUT FEAR AND OTHERS DO NOT
Countries that use it widely have normalised its use as a low-dose analgesic, not as an anaesthetic. They have protocols, training, and accumulated experience.
Countries that do not use it, or use it little, are usually influenced by:
historical memory of toxicity,
absence of local approval,
cost,
lack of direct comparison against alternatives,
availability of ketamine and opioids,
cultural inertia,
medico-legal fear,
or lack of operational pressure to change protocols.
The truth lies in the middle: it is neither a dangerous drug that must always be avoided, nor a panacea that should be given to every patient in pain.
DRRAMONREYESMD VERDICT
Penthrox is an excellent tool for rapid, non-invasive, portable analgesia of moderate to severe traumatic pain in conscious adults, especially in prehospital care, emergency departments, rescue operations, remote medicine, offshore settings, and environments where intravenous access delays pain relief.
Its best role is as early bridge analgesia integrated into a multimodal strategy.
It does not replace ketamine in combat or major trauma. It does not replace opioids in extreme prolonged pain. It does not replace regional blocks when expertise and time exist. It does not replace paracetamol/acetaminophen as baseline analgesia. It does not justify ignoring renal, hepatic, respiratory, neurological, or malignant hyperthermia contraindications.
The mistake would be to dismiss it because of historical fear without understanding the difference between old anaesthetic dosing and modern analgesic dosing.
The opposite mistake would be to use it without pharmacological respect because it looks like a simple inhaler.
In modern medicine, pain must be treated early, properly, and intelligently. Penthrox has a real, useful, and scientifically defensible place within that strategy.
FINAL CONCLUSION
Penthrox methoxyflurane represents one of the most interesting solutions for prehospital and remote analgesia in the 21st century. Its value is not that it is “stronger than everything else”, but that it is rapid, portable, non-invasive, self-administered under supervision, and logistically simple.
In Europe and Spain, it has a clear indication for moderate to severe traumatic pain in conscious adults. In Australia and New Zealand, it has a consolidated tradition. In the United States, it remains conditioned by a complex regulatory history. In TCCC and high-intensity military medicine, it does not displace ketamine because combat requires another level of analgesic robustness.
Serious medicine is not based on trends. It is based on selecting the right tool for the right patient, at the right time, in the right environment.
Penthrox is not for everything.
But where it fits, it fits very well.
DrRamonReyesMD
EMS Solutions International
2026 Update
SOURCES AND REFERENCE URLS
AEMPS CIMA product information: Penthrox 99.9% liquid for inhalation vapour
https://cima.aemps.es/cima/dochtml/ft/82827/ft_82827.html
AEMPS CIMA patient leaflet: Penthrox
https://cima.aemps.es/cima/dochtml/p/82827/P_82827.html
EMA Paediatric Committee decision: Penthrox indication
https://www.ema.europa.eu/en/documents/pip-decision/p-0178-2020-ema-decision-13-may-2020-acceptance-modification-agreed-paediatric-investigation-plan-methoxyflurane-penthrox-emea-000334-pip01-08-m09_en.pdf
Federal Register FDA: Penthrane methoxyflurane withdrawal
https://www.federalregister.gov/documents/2005/09/06/05-17559/determination-that-penthrane-methoxyflurane-inhalation-liquid-999-percent-was-withdrawn-from-sale
TCCC Guidelines 2026
https://learning-media.allogy.com/api/v1/pdf/18ccfdfc-a076-47e9-8a34-376efdd81b43/contents
NHS Highland Penthrox guideline
https://www.rightdecisions.scot.nhs.uk/tam-treatments-and-medicines-nhs-highland/emergency-guidelines/penthrox-methoxyflurane-guidelines/
Australian Commission on Safety and Quality in Health Care: Penthrox
https://www.safetyandquality.gov.au/medicine-finder/penthrox-inhalation
New Zealand Medsafe: Penthrox Data Sheet
https://www.medsafe.govt.nz/profs/datasheet/p/penthroxinh.pdf
Health Canada: Penthrox Product Monograph
https://pdf.hres.ca/dpd_pm/00078480.PDF
HPRA Ireland: Penthrox SmPC
https://assets.hpra.ie/products/Human/29723/Licence_PA22745-001-001_08042025152016.pdf
EUSEM European Pain Initiative Guidelines updated 2025
https://eusem.org/images/251104_EUSEM_European_Pain_Initiative_Guidelines_Updated_Oct_2025.pdf
EMS Solutions International original article
https://emssolutionsint.blogspot.com/2017/02/penthrox-metoxiflurano-analgesico.html
DOI AND SELECTED SCIENTIFIC BIBLIOGRAPHY
Fisher AD et al. Analgesia and sedation for Tactical Combat Casualty Care TCCC proposed change 21-02. Journal of Special Operations Medicine. DOI: 10.55460/8CBI-GAOD
PreMeFen trial protocol. Comparison of inhalational methoxyflurane versus intranasal fentanyl versus intravenous morphine in pre-hospital acute pain management. Trials 2023. DOI: 10.1186/s13063-023-07590-9
Mercadante S et al. Analgesic efficacy, practicality and safety of inhaled low-dose methoxyflurane in acute trauma pain. Open-access review.
https://pmc.ncbi.nlm.nih.gov/articles/PMC6822789/
Qizilbash N et al. Real-world safety of methoxyflurane analgesia in the emergency setting: comparative post-authorisation safety study. BMC Emergency Medicine 2023.
https://pmc.ncbi.nlm.nih.gov/articles/PMC10469512/
Sandberg M et al. Ketamine for the treatment of prehospital acute pain: a systematic review of benefit and harm. BMJ Open 2020. DOI: 10.1136/bmjopen-2020-038134
Miller JP et al. Low-dose ketamine vs morphine for acute pain in the emergency department: randomized controlled trial. American Journal of Emergency Medicine 2015. DOI: 10.1016/j.ajem.2014.12.058
Balzer N et al. Low-dose ketamine for acute pain control in the emergency department: systematic review and meta-analysis. Academic Emergency Medicine 2021. DOI: 10.1111/acem.14159
Guo J et al. Low-dose ketamine versus morphine in the treatment of acute pain in the emergency department: meta-analysis of 15 randomized controlled trials. American Journal of Emergency Medicine 2024. DOI: 10.1016/j.ajem.2023.11.056
Shi X et al. Ketamine in the Management of Acute Pain: A Comprehensive Meta-Analysis. Journal of College of Physicians and Surgeons Pakistan 2024. DOI: 10.29271/jcpsp.2024.01.78
Moradi MM et al. Sub-dissociative-dose ketamine with haloperidol versus fentanyl on pain reduction in acute pain in the emergency department. American Journal of Emergency Medicine 2022. DOI: 10.1016/j.ajem.2022.02.012
Beaudrie-Nunn AN et al. Efficacy of analgesic and sub-dissociative-dose ketamine for acute pain in the emergency department. American Journal of Emergency Medicine 2023. DOI: 10.1016/j.ajem.2023.05.026
Cetin M et al. Nebulized ketamine for acute pain management in the emergency department: systematic review and meta-analysis. American Journal of Emergency Medicine 2025. DOI: 10.1016/j.ajem.2025.04.051
No hay comentarios:
Publicar un comentario